Adil Daud, MD | Authors

A Review of Novel Intralesional Therapies for Melanoma, With an Emphasis on a Potential Combination Approach

May 15, 2016

Perhaps the greatest attraction and chief benefit of intratumoral therapies is their ability to synergize with systemic checkpoint therapies and accelerate the development of a lymphoid infiltrate and perhaps secondary lymphoid structures in vivo, which in turn can result in systemic mobilization of a T-cell response: the local injection–global effect model.